Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the 2024 Cancer Immunotherapy Society

FRAMINGHAM, MA / ACCESSWIRE / October 22, 2024 / (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies that address difficult-to-treat oncology indications, today announced that its abstract has been accepted for poster presentation at the Society of Cancer Immunotherapy (SITC) 39^the Annual Meeting held November 6-10, 2024, in Houston, Texas and virtually.

The presentation details are as follows:

Title: DNase I targeting of neutrophil extracellular traps improves CTLA-4 immune checkpoint blockade in MSS/MMRp CRC models
Abstract number: 765
Presenter: Reid Bissonnette, Ph.D., Executive Consultant for Translational Research and Development at Xenetic
Date and time: Friday, November 8, 2024, 9:00am-7:00pm CST
Location: George R. Brown Convention Center -Level 1 -AB Exhibition Halls

For more information about the conference, visit www.sitcancer.org/2024.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies that address difficult-to-treat cancers. The company’s DNase platform is designed to improve the outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as adjuvant therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

For more information, visit the company website at www.xeneticbio.com and connect on X, LinkedIn and Facebook.

Contact:

JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected]

SOURCE: Xenética Biociências, Inc.

View the original press release at accesswire.com